Statement of Equity, Peptinovo Biopharma Inc. 2023, 2024

Equity	2023			
Common stock boginning balance	2020	Beginning	change	ending
Common stock beginning balance Warrants exercised for common stock Common stock ending balance		9,917	450	10,367
Retained earnings Net loss Earnings		(1,075,883)	(2,832,690)	(3,908,572)
SAFE investment agreements beginning Additional SAFE investments SAFE investments ending balance		1,878,158	123,700	2,001,858
	2023	812,192	(2,708,540)	(1,896,347)
	2024			
Common stock beginning balance Purchase of common stock (Brown) Exercise of options for common stock		Beginning 10,367	3,200 13,544	ending
Common stock ending balance Retained earnings		(3,908,572)		27,111
Net loss Earnings		(0,000,072)	(4,803,155)	(8,711,727)
SAFE investment agreements beginning Converted to Series A preferred shares		2,001,858	(2,001,858)	
SAFE investments ending balance			,	-

2024

(1,896,347)

1,528,189

(368,158)